Adam Veness Sells 3,833 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) SVP Adam Veness sold 3,833 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $110.70, for a total value of $424,313.10. Following the sale, the senior vice president directly owned 3,833 shares of the company’s stock, valued at $424,313.10. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Dianthus Therapeutics Price Performance

Shares of Dianthus Therapeutics stock opened at $112.41 on Thursday. The firm has a market cap of $6.15 billion, a price-to-earnings ratio of -27.09 and a beta of 1.22. The stock has a 50-day simple moving average of $96.25 and a 200-day simple moving average of $82.21. Dianthus Therapeutics, Inc. has a 52-week low of $19.75 and a 52-week high of $114.55.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The firm had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. As a group, equities research analysts predict that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of DNTH. BlackRock Inc. bought a new stake in Dianthus Therapeutics during the second quarter valued at about $401,990,000. Wellington Management Group LLP increased its stake in shares of Dianthus Therapeutics by 3,366.9% in the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after purchasing an additional 2,503,311 shares during the period. Vestal Point Capital LP increased its stake in shares of Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after purchasing an additional 1,499,931 shares during the period. State Street Corp lifted its position in shares of Dianthus Therapeutics by 124.7% during the 4th quarter. State Street Corp now owns 1,507,619 shares of the company’s stock worth $62,129,000 after purchasing an additional 836,571 shares during the last quarter. Finally, Polar Capital Holdings Plc acquired a new position in shares of Dianthus Therapeutics during the 3rd quarter worth about $29,434,000. Institutional investors own 47.53% of the company’s stock.

Analyst Upgrades and Downgrades

DNTH has been the topic of a number of recent research reports. Wedbush raised their price target on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Truist Financial raised their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Dianthus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $124.27.

Trending Headlines about Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains favorable. Truist Financial raised its price target to $128 and maintained a “buy” rating, while the broader analyst consensus is “Moderate Buy” with an average target of $124.27. HC Wainwright also issued an optimistic earnings outlook, potentially supporting DNTH. HC Wainwright earnings outlook
• Positive Sentiment: Institutional ownership trends were generally supportive. AllianceBernstein, Invesco, American Century and Mirae Asset increased their positions during recent quarters, and institutional investors collectively own approximately 47.5% of the company.
• Neutral Sentiment: Short interest was reported at zero shares as of August 11, with a zero-day days-to-cover ratio. This suggests limited short-selling pressure, but also no meaningful short-squeeze catalyst for DNTH.
• Negative Sentiment: Several insiders sold substantial portions of their holdings near $109-$111. SVP Adam M. Veness sold 20,000 shares for approximately $2.21 million, reducing his position by about 81%. Director Anne McGeorge sold 7,750 shares for roughly $845,000, cutting her holdings by 86%, while Director Simon Read sold 2,777 shares for approximately $304,000 and halved his position. The clustered sales may concern investors because they occurred near the stock’s 52-week high. SEC insider trading filing
• Negative Sentiment: Dianthus recently reported a quarterly loss of $0.90 per share, missing the $0.85 consensus estimate. Although revenue of $0.76 million exceeded the $0.30 million forecast, the company remains unprofitable, with analysts expecting a full-year loss of approximately $3.83 per share.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.